Larimar Therapeutics Reports Data From Rare Disease Drug Study
Larimar Therapeutics Reports Data From Rare Disease Drug Study
Larimar Therapeutics發佈稀有病藥物研究數據
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.
專注於開發複雜罕見疾病治療方法的臨床階段生物技術公司Larimar Therapeutics, Inc.（Larimar）（納斯達克股票代碼：LRMR）今天公佈了正在進行的長期OLE研究的積極初步數據，該研究評估了FA參與者每天皮下注射25毫克的nomlabofusp，自行給藥或由護理人員給藥。該公司還提供了nomlabofusp開發計劃的最新情況。